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Inmates in this country represent a large
reservoir of individuals at risk for vaccine-pre-
ventable diseases. Vaccinations are one of the
most cost-effective interventions available,
with the potential for decreasing morbidity and
mortality by preventing or modifying life-threat
ening disease. According to a recent report to
congress1, 11.5 million Americans were
released from jails and prisons in 1998.
Therefore, immunization
efforts targeting inmates
have the potential to
dramatically impact the
health of the incarcerated,
those who work with
them, and the overall pub-
lic health of this nation. 
Not all vaccines are safe
for use in immunocompro-
mised individuals. As a
rule, immunocompro-
mised people should not
receive vaccines based on live-attenuated
organisms. Because of the disproportionately
high prevalence of HIV in jails and prisons, the
use of live attenuated vaccines must be care-
fully considered, as some individuals may not
be aware of their own advanced HIV infection.
On the other hand, the widespread use of
highly active antiretroviral therapy (HAART)
has resulted in immune reconstitution for
many HIV-infected inmates. This may aug-
ment the response to vaccination in these
patients. This article will review the principles,
efficacy, safety and recommendations for
immunizations in HIV-infected individuals.
How vaccines work
The purpose of vaccination is to prevent dis-
ease in the susceptible host. This is done by
stimulating the host's immune system to rec-
ognize the antigens on microorganisms and
produce antibodies or T cell responses capa-
ble of fighting off the microorganisms (immu-
nization).
Vaccines can be classified as live attenuated
vaccines or inactivated vaccines (see Table 1).
Live attenuated vaccines contain microorgan-
isms that replicate and stimulate the host's
immune system but are weakened (attenuat-
ed) so they are generally unable to produce
disease in the immunocompetent individual. In
contrast, inactivated vaccines either contain
organisms killed by heat or chemicals,
or  "subunits" of  these
organisms such as pro-
teins from the cell wall.
With inactivated vac-
cines, there is no risk
of acquiring vaccin-
ation-related disease.
Recombinant vaccines
are a form of inactivated
vaccine derived from
genetically engineered
proteins. These vaccines
do not contain any
microorganisms or their
products. Although they are not technically
vaccines, toxoids are modified bacterial toxins
incapable of producing disease, but able to
stimulate the immune system to prevent the
disease caused by the bacteria.
Vaccination can stimulate CD4 lymphocytes to
become activated. Once in the activated state,
CD4 lymphocytes are more at risk to become
infected by HIV. Thus, vaccination can theo-
retically cause more cells to become infected
by HIV. In the beginning of the AIDS epidemic,
there were concerns that vaccination might
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targeting inmates have 
the potential to dramatically
impact the health of 
the incarcerated, those 
who work with them, 
and the overall public 
health of this nation.
accelerate the progression of HIV. Some
early studies demonstrated that after
receipt of the influenza vaccine or tetanus
toxoid, there was a transient increase
seen in the HIV viral load of vaccinated
individuals.2 However, an abstract pre-
sented at this year's IDSA meeting found
that among patients on HAART with unde-
tectable HIV viral loads who received the
influenza vaccination, there was no
increase in HIV viral load.3 Thus, in the
era of HAART, sustained viral suppression
resulting from effective treatment may
diminish the likelihood of post-vaccination
viral rebound.
Because HIV-infected persons have
altered immune systems, there are spe-
cial safety concerns when considering
vaccination. Live attenuated vaccines can
be problematic due to the potential for
prolonged viral replication in immunocom-
promised individuals. In 1992, an AIDS
patient developed measles pneumonitis
from the measles vaccine.4 In a separate
case, a military recruit with asymptomatic
HIV infection developed disseminated
vaccinia from the smallpox vaccine. 
There are also concerns about the effica-
cy of vaccinations in HIV-infected individ-
uals. Because the immune system can
affect the response to vaccines, there may
be a lack of or reduced response in HIV-
infected individuals. A recent study sug-
gests that viral load suppression is a pre-
dictor of response to vaccinations, regard-
less of the CD4 count. In this retrospective
study, 41 HIV-infected patients received
three doses of the hepatitis B vaccine and
had follow-up hepatitis B serologies per-
formed. Fifty to 60 percent of those
patients who had HIV viral loads <400
copies/mL showed an antibody response,
regardless of their CD4 counts. In those
patients with CD4 counts above 200 and
HIV viral loads >400 copies/mL, only 24%
showed a serological response. The worst
outcomes occurred in patients with CD4
counts <200 and HIV RNA >400
copies/mL, where no patients showed a
response.5 Although this study involved a
small number of patients and the data are
preliminary, it certainly raises concerns
about the efficacy of and ideal time to offer
vaccinations to patients with advanced
immunodeficiency and those with HIV
viral loads >400. 
When to Vaccinate
Many experts recommend vaccinating
HIV-infected individuals early in the
course of HIV disease because of con-
cerns that declining immune status will
reduce the response to vaccination.6
Although the CD4 lymphocyte count is a
surrogate marker for immune status, the
minimal CD4 lymphocyte count needed to
evoke an immune response is unknown.
At low CD4 T-cell counts, HIV-infected
adults may not respond to the initial vac-
cine series and may need additional
(booster) doses of vaccine. If patients are
to be placed on HAART, some experts
recommend delaying vaccination for a few
months after the initiation of therapy since
immune reconstitution from HAART may
result in a better antibody response.
Which Vaccines May Be
Used
Pneumococcal Disease
HIV-infected individuals are at a signifi-
cantly increased risk for both pneumococ-
cal disease and pneumococcal bac-
teremia. Many observational studies in
the U.S. have demonstrated a decrease in
morbidity and mortality among HIV-infect-
ed patients who receive the vaccine.6 The
pneumococcal vaccine is safe to give to
the HIV-infected person because it does
not contain live organisms (bacterial poly-
saccharide vaccine). Therefore, the CDC
recommends vaccinating all HIV-infected
individuals with CD4 lymphocyte counts
>200. The CDC recommends considering
vaccinating HIV-infected individuals with
CD4 lymphocytes <200 although clinical
evidence is lacking. The ACP and AAP
recommend revaccination with a single
dose for children >2 years and adults who
are at highest risk for serious pneumococ-
cal infection and for individuals likely to
have a rapid decline in antibody levels,
provided five years have elapsed since
the first dose. Revaccination every five
years may be prudent in HIV-infected
populations. Although this vaccine is safe,
the efficacy in advanced HIV-infected
patients may be reduced. In cases where
the first vaccination was given when the
CD4 lymphocyte count was <200, revacci-
nation can be considered if the CD4 count
is >200 as a result of HAART, as recom-
mended by the USPHS and IDSA.
Influenza Vaccine
Influenza vaccine is derived from killed
virus. The vaccine is updated every year
based on circulating flu strains. It is safe
for administration to patients who have
HIV and should be given annually to those
who are HIV-infected. The only contraindi-
cation to influenza vaccination is a history
of an anaphylactic hypersensitivity to
eggs or previous vaccination. This vacci-
nation should preferably be administered
every year before influenza season
begins (October through November) but
there is still a potential benefit to those
who receive this vaccination later in the
influenza season (until March).7,8
Hepatitis A and Hepatitis B Vaccines
Both the hepatitis A and B vaccines are
safe in HIV-infected individuals. Hepatitis
A vaccination is recommended for men
who have sex with men, injection drug
users, and persons with chronic liver dis-
ease including hepatitis C.7
The CDC recommends vaccinating all
patients who are infected with hepatitis C
against hepatitis A and B because of the
increased risk of fulminant hepatitis in
these patients. In some correctional insti-
tutions where there is a high prevalence of
2
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Table 1. Classification of Vaccines
Inactivated or Engineered
Vaccines and Toxoids
Inactivated polio vaccine (IPV) 
Hepatitis A vaccine
Hepatitis B vaccine
Influenza vaccine 
Tetanus-Diphtheria (Td) vaccine
Pneumococcal vaccine
H. influenza vaccine (HiB)
Meningococcal vaccine
Rabies vaccine
Live Attenuated Vaccines
Varicella-Zoster virus vaccine (VZV)
Mumps, Measles, and Rubella vaccine (MMR)
Smallpox vaccine (Vaccinia)
Typhoid vaccine
Yellow Fever vaccine
Oral polio vaccine
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Dear Correctional Colleagues:
As HEPP Report approaches its sixth year of publication, it seems the appropriate ti e to
reflect on what we're facing in correctional health care, as well as what we've accomplished.
What we're currently facing is sobering. There are 42 million people living with HIV/AIDS,
worldwide, approximately two million more than last year. Five million new infections worldwide
- 40,000 in the U.S. - occurred in 2002, according to the recently released biannual report from
UNAIDS and the World Health Organization. By the end of 2001, there were 850,000 to
950,000 people living with HIV/AIDS in the U.S.
What we face in prisons and jails reflects these numbers - and more. The Bureau of Justice
Statistics reports a total of 25,088 state and federal inmates known to be HIV positive - and
the number of actual cases is probably higher. In percentages: 2.2% of state prison inmates
and 0.8% of federal prison inmates were known to be infected. What do these numbers mean?
Overall, the rate of confirmed AIDS among the nation's prison populations is four times the rate
in the general population (0.52% in incarcerated communities vs. 0.13% in the general popu-
lation). 
We've also made heartening strides in correctional health care. While there are still more
accomplishments to be made - more widespread testing, more infectious disease specialists
in correctional health care, more comprehensive treatment for all prison populations - we
believe that correctional health care has come a long way in the last five years. 
Even as we look at the enormity of this entire picture, we still believe the best way to
accomplish our mission of improving the level of health care in prisons and jails is to give
correctional health care workers the tools to do it. With that in mind, this month's issue
discusses immunizing HIV-infected patients including vaccines are safe and recommended for
HIV-positive patients (including HIV-positive pregnant women). Considering the large number
of HIV-infected inmates, vaccination may be the safest and most cost-effective way to prevent
a number of vaccine-preventable diseases like HAV, HBV and influenza. 
In this issue, we also provide coverage of reports from IDSA, ICAAC and NCCHC that could
have a bearing on the work we do with infected populations in prison. After reviewing
this issue, readers should be able to identify vaccines that are safe and effective for
HIV populations.
As we wrap up our fifth year of publishing HEPP Report, we want to thank you for your
continued support and as always encourage your feedback, comments, and contributions.
Best wishes for the holiday season and the New Year from all of us at HEPP.
Sincerely, 
Elizabeth Herbert
Letter from the Editor
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4hepatitis C, it may be cost-effective to
vaccinate all HIV-infected inmates for
hepatitis A.
Hepatitis B vaccination is recommended for
all sexually active adults and individuals in
long-term correctional facilities. Hepatitis B
vaccination is neither recommended nor
has been shown to be effective in HbsAg
positive individuals. Because of the high
prevalence of past hepatitis B infection
among inmates, it may be cost-effective to
screen for hepatitis B prior to routine vacci-
nation. Levels of hepatitis B surface anti-
body >10 IU/ml are considered protective
against hepatitis B. People who do not
respond should be revaccinated with an
additional one to three doses.8
The CDC has recommended an alternative
accelerated hepatitis B dosing schedule for
adults. After the first dose, the second dose
should be administered one to two months
later, and the third dose can be adminis-
tered as early as four months after the
first.9
Tetanus Diphtheria (Td) Vaccine
The tetanus diphtheria (Td) vaccine is an
inactivated toxoid and is, therefore, safe to
give to immunocompromised patients.
Even though many inmates will have been
vaccinated as children, they should receive
booster doses every 10 years.
Varicella-Zoster Virus (VZV) Vaccine
Because of the concern for acquiring live
viral infections and transmission of vac-
cine-derived varicella to susceptible popu-
lations, varicella-zoster virus vaccine is
generally not recommended in HIV-infect-
ed adults regardless of their immune sta-
tus. HIV-infected patients who have not
had chickenpox should also avoid contact
with and exposure to varicella (chickenpox)
or zoster (shingles).10 Recommendations
for treating HIV-infected patients who are
exposed to VZV are the same as for preg-
nant women (another group of patients at
risk). Within 96 hours of an exposure to a
patient with varicella or zoster, HIV-infected
adults may receive a prophylactic dose of
varicella-zoster immune globulin (VZIG).
There are no data supporting the use of
antivirals such as acyclovir in this popula-
tion to prevent varicella or zoster.
Measles, Mumps, and Rubella (MMR)
Vaccine
Most HIV-infected individuals will have
received MMR as children, and revaccina-
tion is therefore not routine. The CDC rec-
ommends MMR vaccine be given to HIV-
infected  persons who have not previously
been vaccinated, who are not severely
immunocompromised (CD4 counts >200).
Because of the low prevalence of these
diseases in the U.S. and the potential for
decreased efficacy and disseminated dis-
ease, the risks of the vaccine may
outweigh the benefits. Severely immuno-
suppressed patients exposed to measles
should receive immune globulin (IG)
prophylaxis regardless of their vaccination
status. 
Polio Vaccine
Two types of polio vaccine are available.
The oral polio vaccine is a live virus
vaccine. Because of the risk of polio virus
replication in immunocompromised
patients, it should not be administered to
HIV-infected persons, their household con-
tacts, or nursing personnel who are in close
contact with HIV-infected patients. The
inactivated polio vaccine (IPV) is a suitable
alternative for non-immune immunocom-
promised persons.
HIV-infected Pregnant Woman
When vaccinating HIV-infected pregnant
women, the potential risk to the fetus and to
the mother must be considered. In general,
inactivated vaccines (influenza), bacterial
vaccines (pneumococcal vaccine), and tox-
oids (Td) are safe in pregnancy.
Pregnant women in their second and third
trimesters are at increased risk for serious
complications from influenza and should be
vaccinated before flu season. Hepatitis B
vaccine is recommended for pregnant
women who are at risk for hepatitis B infec-
tion. 
Pneumococcal vaccination is safe and is
recommended in pregnancy for HIV-posi
tive patients who have not been vaccinated
in the past 5 years. In general live virus
vaccines are not recommended for HIV-
infected pregnant women because of the
risk for congenital varicella or rubella and
the risk of disseminated disease in the
mother.7
Conclusion
HIV-infected individuals in correctional
institutions can benefit from receiving vac-
cines to prevent pneumococcal disease,
flu, diphtheria and tetanus, and hepatitis A
and B.  The immune status of the HIV-
infected individuals may influence both the
safety and efficacy of the vaccine. HIV-
infected patients should generally avoid
live-virus or live-bacterial vaccines.
Inactivated vaccines are safe and should
be offered to those who are at risk for dis-
ease. Patients with non-suppressed HIV
viral loads and those with advanced dis-
ease may not respond or may have a blunt-
ed response to vaccination. In general,
vaccines should be avoided during preg-
nancy, if possible. If vaccination must take
place during pregnancy, only inactivated
vaccines should be used. Further research
is needed to evaluate the efficacy and the
safety of vaccines in HIV-infected patients
effectively treated with HAART.
Vaccinations...
(continued from page 2)
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Spotlight: Conference Update - 2002
SEXUALLY TRANSMITTED DISEASES
NCCHC: The recently released report to Congress entitled
"Health Status of Soon to be Released Inmates" highlights the
unique opportunity that correctional health care professionals
have to diagnose and treat sexually transmitted diseases. Data
presented by Kennedy et. al. from seven juvenile detention cen-
ters revealed an average infection prevalence of 7.1% for chlamy-
dia (CT) and 2.6% for gonorrhea (GC). The same group reported
that for incarcerated adult women <25 years-old from three U.S.
cities, the prevalence of CT was 15-22% and that of GC was 8-
9%. Infections were detected utilizing the urine ligase chain assay.
Both CT and GC can be eradicated with a single dose of an antibi-
otic.
NCCHC: Varghese, Lincoln et. al. from the Hamden County
Correctional Center in Massachusetts presented an economic
analysis of an HIV testing and counseling program that demon-
strated that routine testing of inmates is effective in identifying new
cases of HIV, and has the potential to prevent future infections and
decrease health care expenditures.
NCCHC: Newman et. al. presented an epidemiological analysis of
CT and GC in women incarcerated by the Federal Bureau of
Prisons (FBOP). This study demonstrated that in the FBOP, limit-
ing screening to women <31 years of age diagnosed more than
half of the cases at a fraction of the cost of screening all women.
IDSA abstract #29:This CDC study of the HIV counseling and
testing database evaluated the rate of return of HIV test results. In
2000, of 1,641,488 people tested, 15,037 were HIV-infected. Test
results were two times more likely to be returned to people if they
were incarcerated at the time of testing. This data reinforces the
importance of jail and prison-based testing programs. 
IDSA abstract #653:293 HIV-infected individuals with genital
HSV were randomized to receive either twice-daily oral valacy-
clovir or placebo. At six months, 80% of those receiving valacy-
clovir were recurrence-free, opposed to 38% of those receiving
placebo. Genital ulcer disease is known to increase the risk for
transmission of HIV. Thus, the use of prophylactic oral acyclovir or
valacyclovir in those with a history of recurrent genital HSV has
the potential to both decrease recurrence of HSV and transmis-
sion of HIV.
ICAAC: 1494 heterosexual couples discordant for HSV-2 infection
at 96 sites worldwide were randomized so that the HSV-infected
individual received either daily valacyclovir or placebo. The part-
ners of 3.8% of those receiving placebo vs. 1.9% of those receiv-
ing valacyclovir developed infection with HSV. This study suggests
that HSV-2 infected partners of those who are HSV-2 negative
should be offered prophylaxis.
IDSA abstract #662:This San Francisco study found a high inci-
dence of proctitis in a cohort of men who have sex with men. Most
cases were due to syphilis, NG, CT, and/or HSV. As active procti-
tis is known to increase the risk for acquisition of HIV, it should be
promptly diagnosed and treated.
IDSA abstract #655:This study from Seattle found that 33/100
asymptomatic undergraduate men were culture positive for human
papillomavirus (HPV).
IDSA: Exciting news was presented concerning a vaccine to pre-
vent acquisition of HPV. (See also NEJM 11/21/02). Approximately
450,000 women worldwide develop cervical cancer annually, with
a mortality of ~50%. In the developing world, cervical cancer is
one of the leading causes of cancer deaths. In the U.S., ~15,000
cases of cervical cancer occur each year resulting in 5,000
deaths. The vaccine discussed is directed at HPV type 16, which
is responsible for about half of the cases of cervical cancer. The
vaccine was tested on women 16-23 years-old at 16 sites nation-
wide. Women were followed on average for 18 months. Of 768
women vaccinated, none developed HPV type 16 infections or
precancerous lesions. Of the 765 who received placebo, 41 devel-
oped persistent HPV 16 infection and 9 developed precancerous
tissue changes. Vaccinated women developed antibody titers
against HPV 16 that are ~60 times greater than those seen in nat-
urally occurring infection. An international phase 3 study is under-
way utilizing a tetravalent vaccine with serotypes 16, 18, 31, 45.
Together, these four serotypes are responsible for 80% of cervical
cancer.
IDSA abstract #21:The prevalence of flouroquinolone (FQ) resis-
tant GC is known to be high in Asia and Hawaii. This CDC study
of NG at four sites in northern and southern California found an
overall prevalence of resistance to FQ of 4.9%. Higher resistance
rates were seen in Asians, IDU, and those with recent antibiotic
use. Therefore, FQ can no longer be considered first-line therapy
for NG in CA or for patients who acquired GC there.
NCCHC: Clark, Sylla, and Gaylord presented a one-year report on
the L.A. County jail condom distribution program. This initiative,
which provides condoms and risk reduction education to self-iden-
tified gay, bisexual, and transgendered inmates, has been well
accepted by staff and inmates and lead to no disciplinary issues.
HEPATITIS
IDSA abstract #793:The HCV seroprevalence among incoming
inmates to the NYS prison system in 2000-2001 was 23% among
women and 13.4% among men. The rate of HIV co-infection was
5.6% in women and 2.3% in men. Even among non-IDUs, the
prevalence of HCV was 14% in women and 9% in men. This data
suggests that inmates should be counseled and screened for HCV
even in the absence of identified high-risk behaviors.
IDSA abstract #517:This study of HCV prevalence among the
urban poor in San Francisco demonstrated a prevalence of HCV
of 69%. Patients were recruited from hotels, shelters, and free
lunch sites. Among those infected with HCV, a history of treatment
was rare with <2% of patients entering into treatment each year.
Continued on page 6
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Selected news from the 42nd Interscience Conference on Antimicrobial Chemotherapy (ICAAC) held September 27-30,
2002 in San Diego; the 26th annual meeting of the National Commission on Correctional Health Care (NCCHC) held
October 19-23, 2002 in Nashville; and the 40th conference of the Infectious Diseases Society of America (IDSA) held
October 24-27, 2002 in Chicago.1
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IDSA abstract #527:Among HIV-infected patients vaccinated for
HAV, only 60% developed a protective antibody titer. Those with
CD4 >200 were two times more likely to respond to vaccination.
ICAAC and IDSA: Both had numerous abstracts looking at use of
3TC, adefovir, and/or tenofovir in the treatment of chronic hepati-
tis B infection. All three agents have the potential to decrease
HBV viral load and liver inflammation. In a minority of patients,
loss of e antigen positivity can be achieved. Studies are ongoing
utilizing combination therapy targeted at HBV in mono-infected
and HIV co-infected patients. 
HAART: TREATMENT-NAÏVE PATIENTS
ICAAC: Follow-up data was presented from Gilead 903 demon-
strating that at 48 weeks, 80% of those receiving efavirenz (EFV)
plus 3TC plus either d4T or tenofovir had HIV VL <50 copies.
Previously, ACTG 384 established that in terms of time to virolog-
ic failure, AZT/3TC/EFV is superior to AZT/3TC/NFV,
d4T/ddI/NFV, or d4T/ddI/EFV in treatment-naïve patients.
Considered together, these studies further support the use of an
EFV/3TC backbone coupled with abacavir, AZT, ddI, d4T, or teno-
fovir in the treatment of HAART-naïve patients. 
ICAAC H-1076:BMS A1424-034 data was presented comparing
AZT/3TC/EFV to AZT/3TC/atazanavir (BMS's new once-a-day
protease inhibitor.) As compared to other PI regimens, atazanavir
(ATZ) has been shown to lead to minimal lipid changes. ATZ can
cause asymptomatic elevations in indirect bilirubin. 
Previous studies suggested that virologically, ATZ has efficacy
similar to nelfinavir (NFV), while NFV has been shown to be less
effective in naïve patients than EFV. Surprisingly, A1424-034
found that both the ATZ and EFV arms had comparable efficacy
in achieving HIV VL of <400 and <50. It should be noted howev-
er that both arms were significantly less successful than has been
seen in prior EFV studies. (HIV VL <400: 70% in the ATZ arm,
64% in the EFV arm; HIV VL <50: 32% in the ATV arm, 37% in
the EFV arm). Although a true once daily PI is a welcome addi-
tion, further study is needed before ATZ can be considered to be
virologically equivalent to EFV.
ICAAC H-165: Through four years of follow-up, HAART-naïve
patients receiving Lopinavir-ritonavir (LPV-rtv) demonstrated sus-
tained virologic response (intent to treat analysis: 70% HIV VL
<50; on treatment analysis, 97% VL <50). Of those with viral load
rebound, no PI resistance mutations have been demonstrated.
LPV was well tolerated.
ICAAC H-161:554 treatment-naïve patients were randomized to
300 mg po qd or 150 mg bid of 3TC coupled with once-daily EFV
and twice-daily AZT. At 48 weeks, both arms demonstrated equiv-
alent antiviral efficacy, adverse events, and frequency of the 184
mutation. 3TC has now been approved for once-a-day dosing,
and a new 300 mg formulation is available. 
ICAAC H-166:Fosamprenavir is a prodrug of amprenavir (APV)
that is well tolerated, has no food restrictions, and is dosed as two
pills bid as compared to eight bid for APV. The NEAT trial was
reported at ICAAC, and demonstrated comparable virologic effi-
cacy for fosAPV/3TC/ABC as compared to NFV/3TC/ABC. 
HAART: TREATMENT-EXPERIENCED
PATIENTS
ICAAC: Toro 2 studied HAART-experienced patients in Europe
and Australia who are resistant to medications in all three classes
and/or have a history of prolonged use of HAART. This study eval-
uated the addition of T-20 (fusion inhibitor) by bid injection vs.
placebo to an optimized background of three to five other agents.
The T-20 arm demonstrated a 1.70 decrease in the HIV VL as
compared to a .76 drop in the optimized background arm alone.
HAART: SIDE EFFECTS
ICAAC H-1074: This study looked at the result of substituting
ABC or AZT for d4T in patients with either lipoatrophy (as deter-
mined by self-report or physical examination) or elevated serum
lactate (>3.2 without symptoms, >2.2 with symptoms). Patients
were studied by dexa scan, CT, self-report, and anthropomorphic
measurements. Patients who switched from d4T demonstrated
increased fat in arms and legs by dexa scanning; decreased lac-
tate levels; and significant improvements in lipoatrophy (by self
report) with increased fat in face, legs, arms, and buttocks.
ICAAC: Previously, the Gilead 903 study demonstrated equiva-
lent virologic efficacy of EFV/3TC/TFV vs. EFV/3TC/d4T. At
ICAAC, further analysis of this study was presented which
showed that the d4T arm had an increased incidence of elevated
serum lactate,  hyperlipidemia, (cholesterol, fasting triglycerides,
LDL), and neuropathy as compared to the TFV arm. 
Disclosures:
*Nothing to disclose.
References:
1. This article contains discussion of off-label use of some drugs; not all
have been approved for that use by the FDA.
Conference Update...
(continued from page 5)
Resources & Websites
Diagnosis and Management of Hepatitis C
CME activity
http://www.medscape.com/clinicalupdate/hepc
HIV in Prisons, 2000
Bureau of Justice Statistics 
http://www.ojp.usdoj.gov/bjs/abstract/hivp00.htm
Viral Hepatitis Education for Correctional Facilities
Hepatitis educational curriculum for correctional health care
providers and inmates. 
http://www.cdc.gov/ncidod/diseases/hepatitis/spotlights/ncchc.htm
Infectious Diseases Society of America (IDSA)
http://www.idsociety.org/
American Association for the Study of Liver Disease
http://www.aasld.org/
Conference Reports
AASLD, ICAAC, IDSA
http://www.hivandhepatitis.com/
http://www.natap.org/
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Some facilities holding the largest number of prisoners with confirmed AIDS
Number of inmates on June 30, 2000 State Total With confirmed AIDS   % of all inmates
Total 56,021 1,995 3.6 
CA Men's Colony CA 6,683 63 0.9 
CA State (Corcoran) CA 5,840 51 0.9 
Osborn CI CT 1,818 64 3.5 
Central FLA Reception Ctr FL 2,174 140 6.4 
Washington CI FL 1,178 78 6.6 
Everglades CI FL 1,537 61 4.0 
Apalachee CI FL 1,611 60 3.7 
Union CI FL 1,703 54 3.2 
Okeechobee CI FL 1,147 50 4.4 
Taylor CI FL 1,006 48 4.8 
Martin CI /Work Camp FL 1,057 42 4.0 
Lake CI FL 1,055 39 3.7 
Wheeler CF - CCA GA 1,002 50 5.0 
Reception Diagnostic Ctr IN 668 50 7.5 
Elayn Hunt Correctional Ctr LA 2,151 43 2.0 
Louisiana State Pen. LA 5,116 41 0.8 
Roxbury CI MD 1,906 67 3.5 
Metropolitan Transition Ctr MD 1,604 40 2.5 
Mississippi State Pen. MS 4,986 49 1.0 
Mohawk CF NY 1,408 111 7.9 
Albion CI NY 1,342 41 3.1 
Attica CF NY 2,211 40 1.8 
Broad River CI SC 989 217 21.2 
Stiles Unit TX 2,856 452 15.8 
Estelle Unit TX 2,973 44 1.5
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World AIDS Day 2002: Correctional Update
World AIDS Day was commemorated around the globe on December 1st to celebrate progress made in the battle against the epi-
demic, and focus attention on remaining challenges. The problem of HIV/AIDS in prisons and jails is still overlooked by World AIDS
Day community efforts, and we feel it is important to both celebrate the strides made in HIV/AIDS care in correctional settings, and
recognize our ongoing challenges. The first table below gives us heartening news: the marked decline in the percentage of AIDS
deaths in U.S. correctional facilities by state. The second table shows us the progress still to be made: the prevalence data in the 25
correctional facilities in the U.S. holding the largest number of inmates with confirmed AIDS. The following tables were created with
data from the Bureau of Justice Statistics Bulletin "HIV in Prisons, 2000" (October 2002).  
Source: Data are from the 2000 Census of State and Federal Adult Correctional Facilities. A total of 1,504 facilities reported data on confirmed AIDS.
8Vaccine
Live
MMR
Varicella (VZV)
OPV
Inactivated
Pneumococcal
Tetanus-Diphtheria (Td)
Influenza
Hepatitis A
Hepatitis B
IPV
CD4 <200
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
CD4 >200
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
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When to Immunize Inmates
Recommendations for Immunizations in HIV-infected Inmates 
Vaccine
Live
MMR
Varicella (VZV)
OPV
Inactivated
Pneumococcal
Tetanus-Diphtheria (Td)
Influenza
Hepatitis A
Hepatitis B
IPV
CD4 <200
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
CD4 >200
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Recommendations for Immunizations in HIV-infected Pregnant Inmates
Tetanus, Diphtheria(Td)
Influenza
Pneumococcal
Hepatitis A(Havrix, Vaqta)
Hepatitis B(Engerix-B, 
Recombivax HB)
Hepatitis A/B combination (Twinrix)
Measles, Mumps, Rubella (MMR)
1 dose booster every 10 years
1 annual dose
1 dose for persons with medical or other indications. (1 dose revaccination for
immunosuppressive conditions)
2 doses (0, 6-12 months) for persons with medical, behavioral, occupational or
other indications, including hepatitis C infection
3 doses (0, 1-2, 4-6 months) for persons with medical, behavioral, occupational,
or other indications, including hepatitis C infection
3 doses (0, 1-2, 4-6 months) for persons with medical, behavioral, occupational,
or other indications, including hepatitis C infection
1 dose if MMR vaccination history is unreliable; 2 doses for persons with occu-
pational or other indications
CDC's Recommended Adult Immunization Schedule, 2002-2003
North American AIDS
Treatment Action Forum
December 8-11, 2002
New Orleans, Louisiana 
Fee: $225
Call: Paul Woods,
202.483.6622 ext. 343
Email: pwoods@nmac.org
Visit: www.nmac.org/nataf/2002
American Correctional
Association Winter Conference
January 11-15, 2003
Charlotte, North Carolina
Call: 800.222.5646 ext. 1922
Visit: www.aca.org
Hepatitis C Management for
Prisoners
January 25-26, 2003
San Antonio, Texas
For abstract forms and more 
information, visit
http://www.med.umn.edu/cme/htm
l/hepcoordinators.html
National Hepatitis
Coordinators' Conference
January 26-30, 2003
San Antonio, Texas
Fee: $125
Call: 800.776.8636
http://www.med.umn.edu/cme/
brochures2002/hepcoord2003/
hepcoordbro2003.html
10th Conference on
Retroviruses and Opportunistic
Infections
February 10-14, 2003
Boston, Massachusetts
Call: 703.535.6862
Email: info@retroconference.org
Visit: http://www.retroconference.
org/2003
Management of HIV/AIDS in the
Correctional Setting 
Satellite Video Conference
Hepatitis B & C with 
HIV Co-infection: A Diagnostic &
Treatment Update
March 11, 2003
12:30-3:30 p.m. E.T.
CME & Nursing Credits Available
www.amc.edu/Patient/HIV/
hivconf.htm
E-mail: ybarraj@mail.amc.edu
Call: 518.262.4674
Save the 
Dates
9
New Guidelines for Metabolic
Complications Associated with HIV
The International AIDS Society-USA published
its first comprehensive guidelines for metabolic
complications associated with HIV and anti-
retroviral therapy. The guidelines appear in the
Nov. 4 issue of the Journal of Acquired Immune
Deficiency Syndromesand include recommen-
dations for assessing, monitoring and treating
metabolic problems in five areas: abnormal fat
distribution, lactic acid disorders, bone disease,
abnormalities in lipid metabolism, and insulin
resistance with alternations in glucose metabo-
lism. www.kaisernetwork.org, 11/6/02
FDA Accepts New Drug Application for HIV 
The FDA has accepted North Carolina-based
Triangle Pharmaceuticals' new drug application
for the antiretroviral drug Coviracil. According
to Triangle, the drug (a nucleoside reverse tran-
scriptase inhibitor) could be approved for mar-
keting in the U.S. as soon as the third quarter
of 2003. www.kaisernetwork.org, 11/6/02
20-minute HIV Test Approved by FDA
The FDA has approved OraSure's easy-to-use
20-minute HIV test, OraQuick. According to the
FDA, studies show OraQuick is 99.6 percent
accurate. The test involves pricking a person's
finger and gives results similar to common
pregnancy tests. People who test positive need
a lab test to confirm HIV infection. OraSure will
begin selling the test at the end of this year and
at first it will be available only in hospitals and
large health clinics. Associated Press, 11/8/02
HIV Cases "Soar" in MD State Prisons
According to a recent U.S. Department of
Justice Report, Maryland had the second-high-
est percentage of HIV-positive prisoners in the
nation, second only to New York. Of the state's
more than 23,200 prisoners, 4.3% (998
inmates) were known to be HIV-positive in
2000, a 21% increase from the 820 HIV-posi
tive inmates the year before. Local AIDS offi-
cials attribute the growing problem to high rates
of injection drug use and needle sharing among
addicts in Maryland’s urban areas.
www.aegis.org, 11/11/02
HCV Viremia in HIV+, HCV-Seronegative
Patients
A recent article in the Journal of Acquired
Immune Deficiency Syndromes(2002; 31(2):
154-162) reviews a study that found that HCV
viremia may occur in patients without
detectable HCV antibodies. The study con-
cludes that HCV infection appears to occur
more frequently among HIV-infected, HCV-
seronegative patients than previously thought.
www.natap.org, 11/18/02
Trends in HCV and HIV in Inmates Entering
CA Prisons
A report in the November 2002 issue of AIDS
studies trends in HCV and HIV infection among
inmates entering prison in California in 1994
and 1999. Among other trends, men were more
likely to be infected with HCV than were
women, but there was a 16% increase in HCV
positivity among African-American men. And
HIV seroprevalence decreased from 1994 to
1999 for both men and women, but compared
with white and Latino inmates, African-
American male and female inmates were more
likely to be infected with HIV in 1999. AIDS,
November 2002
Study Tests Pegasys/Ribavirin in African-
Americans
Lennox Jeffers compared the efficacy and safe-
ty of Pegasys/Ribavirin combination therapy for
treating African-American and Caucasian
patients infected with the HCV genotype 1. The
study followed 78 African-Americans and 28
Caucasians over 48 weeks (with a 24-week fol-
low-up period). Investigators concluded that
while African-Americans appear to tolerate the
therapy better than Caucasians, African-
Americans appear to have lower response
rates. www.natap.org, 11/11/02
Maryland Officials Studying How to Test,
Tr at Inmates for HCV
Maryland correctional officials have created a
ta k force to draft a new state policy for testing
and treating inmates with hepatitis C. The state
does not require inmates to be tested for HIV or
HCV, and there is no set treatment policy for
prisoners infected with HCV. While there are no
statistics for how many inmates in MD are
infected with HCV, the state has the second-
highest rate of HIV infection among inmates,
and the "close association" between HIV and
HCV suggests that treating all HCV infected
inmates would be expensive.
Associated Press, 11/12/02
Inmate's TB Prompts Widespread Testing
More than 150 inmates and correctional staff
were tested for tuberculosis (TB) after the dis-
covery of TB in an inmate at the state prison in
Lansing, Kansas. Of the 154 people tested, 27
tested positive for TB infection, though none
have developed full-blown TB, according to
health officials. The infected inmate had been
housed in several county jails, leading to the
widespread testing. 
Associated Press, 10/29/02
Syphilis Rate Rises in U.S.
Syphilis cases in the U.S. are on the rise for the
first time in more than a decade, the CDC
reports. The syphilis rate increased from 2.1
cases per 100,000 people in 2000 to 2.2 cases
per 100,000 last year; more than two-thirds of
the new syphilis patients were men. The trend
suggests a potential resurgence in transmis-
sion of the AIDS virus, the CDC said. 
MMWR, 11/1/02
Inside News
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through June 30, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. It is generally considered safe to vaccinate HIV-infected 
persons:
(a) In all cases
(b) In some cases
(c) In no cases
2. An abstract presented at this year's IDSA meeting found that
among patients on HAART with undetectable HIV viral loads and
who received the influenza vaccination, there was no increase in
HIV viral load. 
(a) True
(b) False
3. Non-immune, HIV-infected patients can be safely immunized
with the following vaccines:
(a) Influenza, hepatitis A, hepatitis B, and VZV
(b) Hepatitis A, hepatitis B, Pneumococcal, IPV
(c) Pneumococcal, Influenza, DTP, and MMR
(d) OVP, Influenza, hepatitis A, hepatitis B
4. Vaccines not recommended for HIV-infected individuals
include:
(a) VZV
(b) OPV
(c) Pneumococcal
(d) A and B
(e) None of the above
5. The following type of vaccines are not recommended for HIV-
infected pregnant women:
(a) Live attenuated virus vaccines
(b) Toxoids
(c) Bacterial vaccines
d) Inactivated vaccines
6. The following types of patients may not respond or will have a
blunted response to vaccination:
(a) Pregnant women
(b) HCV-positive patients
(c) Patients with non-suppressed HIV viral loads
(d) HAART-experienced patients
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HIV 101 5  4  3  2  1   5  4  3  2  1  
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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